| Trial ID: | L5317 |
| Source ID: | NCT04286399
|
| Associated Drug: |
Renin-Angiotensin-Aldosterone System Inhibitors
|
| Title: |
Asian Diabetes Outcomes Prevention Trial
|
| Acronym: |
ADOPT
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus|Cardiovascular Diseases
|
| Interventions: |
DRUG: Renin-angiotensin-aldosterone system inhibitors|DRUG: Beta blocker|DRUG: SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product
|
| Outcome Measures: |
Primary: Combined endpoint based on the first occurrence of cardiovascular death or major adverse cardiovascular event, Stroke/myocardial infarction/heart failures events, 48 months |
|
| Sponsor/Collaborators: |
Sponsor: National Heart Centre Singapore | Collaborators: Singapore General Hospital|Mackay Memorial Hospital|National Taiwan University Hospital|Peking University People's Hospital|Medanta, The Medicity, India|Public Health Foundation of India|Putrajaya Hospital, Malaysia|Universiti Teknologi Mara
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
2400
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2019-07-01
|
| Completion Date: |
2034-06-30
|
| Results First Posted: |
|
| Last Update Posted: |
2021-04-30
|
| Locations: |
Singapore General Hospital (SGH), Singapore, 169608, Singapore
|
| URL: |
https://clinicaltrials.gov/show/NCT04286399
|
